Top

Cellular Oncology

Published in:

01-06-2018 | Original Paper

Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer

Authors: Katarzyna Starska, Ewa Forma, Iwona Lewy-Trenda, Olga Stasikowska-Kanicka, Michał Skóra, Magdalena Bryś

Published in: Cellular Oncology | Issue 3/2018

Abstract

Purpose

Aberrant fibroblast growth factor receptor (FGFR) expression is thought to contribute to the development of many types of cancer. As yet, however, their impact on the course and prognosis of head and neck cancer remains to be determined. Here, we aimed to investigate the effects of expression of the FGFR family members FGFR1 and FGFR3, as well as their downstream PI3K/AKT signal-regulated kinases, on the aggressiveness and prognosis of laryngeal cancer.

Methods

In total 137 surgically removed squamous cell laryngeal cancer (SCLC) and 100 matched non-cancerous laryngeal mucosa (NCLM) samples were assessed for mRNA expression using quantitative real-time PCR. The corresponding proteins were analyzed by Western blotting. SLUG expression was assessed by immunohistochemistry. The expression data were subsequently related to tumor front grading (TFG), local/nodal recurrences, prognosis and overall survival.

Results

The FGFR1, FGFR3 and PI3K/AKT kinase mRNA and protein levels were found to be significantly higher in the SCLC than the NCLM samples (p < 0.05). A high FGFR1 mRNA/protein expression level was found to be associated with an increased invasion rate, according to TFG scale and SLUG level, a high local/nodal recurrence rate and a poor prognosis (p < 0.05). Similarly, we found that a high FGFR3 mRNA/protein expression level was associated with a shorter survival time (p < 0.05). In addition, we found that high PI3K/AKT kinase mRNA/protein levels were associated with a high TFG (p < 0.05). We also found that FGFR1/3 mRNA and FGFR1 protein levels were inversely associated with overall survival (log-rank test: FGFR1 mRNA p = 0.03, FGFR3 mRNA p = 0.04, FGFR1 protein p = 0.03). Subsequent multivariate analyses revealed that high FGFR3 mRNA expression may serve as an independent poor prognostic factor (HR 2.32, 95% CI 1.03–6.59; p = 0.04). We also found that the p-PI3K regulatory kinase protein level was significantly associated with survival in the cohort studied (HR 1.78, 95% CI 0.64–8.53; p = 0.03).

Conclusions

From our data we conclude that FGFR1 and FGFR3, as well as its downstream regulatory PI3K/AKT kinases, may serve as potential biomarkers for the invasiveness and prognosis of laryngeal cancer. The expression of FGFR1/3-PI3K/AKT regulatory pathway members may be instrumental for the identification of patients at risk for an unfavorable clinical outcome.

Available only for authorised users

B.W. Stewart, C.P. Wild, World Cancer Report 2014 (Lyon, France, International Agency for Research on Cancer, 2015), IARC Publications Website: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014

K.D. Miller, R.L. Siegel, C.C. Lin, A.B. Mariotto, J.L. Kramer, J.H. Rowland, K.D. Stein, R. Alteri, A. Jemal, Cancer treatment and survivorship statistics. CA Cancer J. Clin. 66, 271–289 (2016)CrossRefPubMed

R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics. CA Cancer J. Clin. 66, 7–30 (2016)CrossRefPubMed

S. Bhattacharyya, V. Sekar, B. Majumder, D.G. Mehrotra, S. Banerjee, A.K. Bhowmick, N. Alam, G.K. Mandal, J. Biswas, P.K. Majumder, N. Murmu, CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer. Cell Oncol 40, 145–155 (2017). https://doi.org/10.1007/s13402-016-0311-7

L. Kadletz, G. Heiduschka, R. Wiebringhaus, E. Gurnhofer, U. Kotowski, G. Haymerle, M. Brunner, C. Barry, L. Kenner, ELMO3 expression indicates a poor prognosis in head and neck squamous cell carcinoma-a short report. Cell Oncol 40, 193–198 (2017). https://doi.org/10.1007/s13402-016-0310-8

L. Zhou, L.T. Yao, Z.Y. Liang, W.X. Zhou, L. You, Q.Q. Shao, S. Huang, J.C. Guo, Y.P. Zhao, Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Int. J. Clin. Exp. Pathol. 8, 14640–11468 (2015)PubMedPubMedCentral

X. Liu, W. Zhang, D. Geng, J. He, Y. Zhao, L. Yu, Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet. Mol. Res. 13, 1109–1120 (2014)CrossRefPubMed

J.Y. Sung, J.M. Sun, B. Chang Jeong, S. Il Seo, S. Soo Jeon, H. Moo Lee, H. Yong Choi, S. Young Kang, Y.L. Choi, G. Young Kwon, FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol. Oncol. 32, 49.e23–49.e31 (2014). https://doi.org/10.1016/j.urolonc.2013.07.015 CrossRef

C. Poyet, T. Hermanns, Q. Zhong, E. Drescher, D. Eberli, M. Burger, F. Hofstaedter, A. Hartmann, R. Stöhr, E.C. Zwarthoff, T. Sulser, P.J. Wild, Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer. Oncol. Lett. 10, 2753–2760 (2015)CrossRefPubMedPubMedCentral

10.

E.A. Guancial, L. Werner, J. Bellmunt, A. Bamias, T.K. Choueiri, R. Ross, F.A. Schutz, R.S. Park, R.J. O'Brien, M.S. Hirsch, J.A. Barletta, D.M. Berman, R. Lis, M. Loda, E.C. Stack, L.A. Garraway, M. Riester, F. Michor, P.W. Kantoff, J.E. Rosenberg, FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 3, 835–844 (2014)CrossRefPubMedPubMedCentral

11.

K. Koole, P.M. van Kempen, J.E. Swartz, T. Peeters, P.J. van Diest, R. Koole, R.J. van Es, S.M. Willems, Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma. Cancer Med. 5, 275–284 (2016)CrossRefPubMed

12.

F. Göke, M. Bode, A. Franzen, R. Kirsten, D. Goltz, A. Göke, R. Sharma, D. Boehm, W. Vogel, P. Wagner, C. Lengerke, G. Kristiansen, J. Kirfel, T. Van Bremen, F. Bootz, L.E. Heasley, A. Schröck, S. Perner, Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod. Pathol. 26, 1298–1306 (2013)CrossRefPubMed

13.

H.S. Kim, S.E. Lee, Y.S. Bae, D.J. Kim, C.G. Lee, J. Hur, H. Chung, J.C. Park, D.H. Jung, S.K. Shin, S.K. Lee, Y.C. Lee, H.R. Kim, Y.W. Moon, J.H. Kim, Y.M. Shim, S.S. Jewell, H. Kim, Y.L. Choi, B.C. Cho, Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 6, 2562–2572 (2015)PubMed

14.

S. Bertz, C. Abeé, S. Schwarz-Furlan, J. Alfer, F. Hofstädter, R. Stoehr, A. Hartmann, A.K. Gaumann, Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Arch. 465, 687–695 (2014)CrossRefPubMed

15.

M. Inokuchi, Y. Fujimori, S. Otsuki, Y. Sato, M. Nakagawa, K. Kojima, Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. Gastroenterol Res Pract 2015, 796380 (2015). https://doi.org/10.1155/2015/796380 CrossRefPubMedPubMedCentral

16.

M. Katoh, FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis. Int. J. Mol. Med. 38, 3–15 (2016)CrossRefPubMedPubMedCentral

17.

A. Desai, A.A. Adjei, FGFR signaling as a target for lung cancer therapy. J. Thorac. Oncol. 11, 9–20 (2016)CrossRefPubMed

18.

R. Dienstmann, J. Rodon, A. Prat, J. Perez-Garcia, B. Adamo, E. Felip, J. Cortes, A.J. Iafrate, P. Nuciforo, J. Tabernero, Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 25, 552–563 (2014)CrossRefPubMed

19.

F. Biello, G. Burrafato, E. Rijavec, C. Genova, G. Barletta, A. Truini, S. Coco, M.G. Bello, A. Alama, F. Boccardo, F. Grossi, Fibroblast growth factor receptor (FGFR): a new target for non-small cell lung cancer therapy. Anticancer Agents Med. Chem. 16, 1142–1154 (2016)CrossRefPubMed

20.

C. Hierro, J. Rodon, J. Tabernero, Fibroblast growth factor (FGF) Receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors. Semin. Oncol. 42, 801–819 (2015)CrossRefPubMed

21.

T. Helsten, M. Schwaederle, R. Kurzrock, Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 34, 479–496 (2015)CrossRefPubMedPubMedCentral

22.

E. Martino, D. Tomlinson, M. Knowles, A decade of FGF receptor research in bladder cancer: past, present, and future. Adv. Urol. 2012, 429213 (2012). https://doi.org/10.1155/2012/429213 CrossRefPubMedPubMedCentral

23.

D. Tomlinson, E. Baxter, P. Loadman, M.A. Hull, M.A. Knowles, FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCγ/COX-2-mediated mechanisms. PLoS One 7, e38972 (2012). https://doi.org/10.1371/journal.pone.0038972

24.

A. Parish, M. Schwaederle, G. Daniels, D. Piccioni, P. Fanta, R. Schwab, K. Shimabukuro, B.A. Parker, T. Helsten, R. Kurzrock, Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle 14, 2121–2128 (2015)CrossRefPubMedPubMedCentral

25.

W. Zhou, Y. Zhu, S. Chen, R. Xu, K. Wang, Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma. Mol. Med. Rep. 13, 713–719 (2016)CrossRefPubMed

26.

L. Huang, Z. Huang, Y. Fan, L. He, M. Ye, K. Shi, B. Ji, J. Huang, Y. Wang, Q. Li, FOXC1 promotes proliferation and epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway. Am. J. Transl. Res. 9, 1297–1306 (2017)PubMedPubMedCentral

27.

C. Wang, W. Gu, Y. Zhang, Y. Ji, Y. Wen, X. Xu, Nicotine promotes cervical carcinoma cell line HeLa migration and invasion by activating PI3k/Akt/NF-κB pathway in vitro. Exp Toxicol Pathol 69, 402–407 (2017). https://doi.org/10.1016/j.etp.2017.03.006

28.

L. Chen , H. Fu H, Y. Luo, L. Chen, R. Cheng, N. Zhang, H. Guo, cPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling. Cell Death Dis (2017) doi: https://doi.org/10.1038/cddis.2017.152, 8, 4, e2728

29.

Y. Li, G. Guo, J. Song, B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K/Akt/STAT3 signaling pathway. J. Cancer 8, 816–824 (2017)CrossRefPubMedPubMedCentral

30.

J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269), pl1 (2013). https://doi.org/10.1126/scisignal.2004088 CrossRefPubMedPubMedCentral

31.

The Cancer Genome Atlas Network (TCGA), Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015). https://doi.org/10.1038/nature14129 (online document http://www.cbioportal.org/study?id=hnsctcga#summary. Accessed 14 September 2017)CrossRef

32.

L.G.T. Morris, R. Chandramohan, L. West, A. Zehir, D. Chakravarty, D.G. Pfister, R.J. Wong, N.Y. Lee, E.J. Sherman, S.S. Baxi, I. Ganly, B. Singh, J.P. Shah, A.R. Shaha, J.O. Boyle, S.G. Patel, B.R. Roman, C.A. Barker, S.M. McBride, T.A. Chan, S. Dogan, D.M. Hyman, M.F. Berger, D.B. Solit, N. Riaz, A.L. Ho, The molecular landscape of recurrent and metastatic head and neck cancers insights from a precision oncology sequencing platform. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.1790 (online document http://www.cbioportal.org/study?id=hncmskcc2016# summary. Accessed 14 September 2017)

33.

N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, G.V. Kryukov, M.S. Lawrence, C. Sougnez, A. McKenna, E. Shefler, A.H. Ramos, P. Stojanov, S.L. Carter, D. Voet, M.L. Cortés, D. Auclair, M.F. Berger, G. Saksena, C. Guiducci, R.C. Onofrio, M. Parkin, M. Romkes, J.L. Weissfeld, R.R. Seethala, L. Wang, C. Rangel-Escareño, J.C. Fernandez-Lopez, A. Hidalgo-Miranda, J. Melendez-Zajgla, W. Winckler, K. Ardlie, S.B. Gabriel, M. Meyerson, E.S. Lander, G. Getz, T.R. Golub, L.A. Garraway, J.R. Grandis, The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011) (online document http://www.cbioportal.org/study?id=hnsc broad#summary. Accessed 14 Sept 2017)

34.

N.A. Ipenburg, K. Koole, K.S. Liem, P.M. van Kempen, R. Koole, P.J. van Diest, R.J. van Es, S.M. Willems, Fibroblast growth factor receptor family members as prognostic biomarkers in head and neck squamous cell carcinoma: a systematic review. Target Oncol. 11, 17–27 (2016)CrossRefPubMed

35.

F. Göke, A. Franzen, T.K. Hinz, L.A. Marek, P. Yoon, R. Sharma, M. Bode, A. von Maessenhausen, B. Lankat-Buttgereit, A. Göke, C. Golletz, R. Kirsten, D. Boehm, W. Vogel, E.K. Kleczko, J.R. Eagles, F.R. Hirsch, T. Van Bremen, F. Bootz, A. Schroeck, J. Kim, A.C. Tan, A. Jimeno, L.E. Heasley, S. Perner, FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin. Cancer Res. 21, 4356–4364 (2015)CrossRefPubMedPubMedCentral

36.

B.N. Tillman, M. Yanik, A.C. Birkeland, C.J. Liu, D.H. Hovelson, A.K. Cani, N. Palanisamy, S. Carskadon, T.E. Carey, C.R. Bradford, S.A. Tomlins, J.B. McHugh, M.E. Spector, J.C. Brenner, Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing. Head Neck 38(Suppl 1), E1646–E1652 (2016). https://doi.org/10.1002/hed.24292 CrossRefPubMedPubMedCentral

37.

Y. Yu, T. Hall, S. Eathiraj, M.J. Wick, B. Schwartz, G. Abbadessa, In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anti-Cancer Drugs 28, 503–513 (2017). https://doi.org/10.1097/CAD.0000000000000486

38.

S. Feng, L. Shao, P. Castro, I. Coleman, P.S. Nelson, P.D. Smith, B.R. Davies, M. Ittmann, Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. Oncotarget 8, 6179–6192 (2017)PubMed

39.

J.J. Wheler, J.T. Atkins, F. Janku, S.L. Moulder, P.J. Stephens, R. Yelensky, V. Valero, V. Miller, R. Kurzrock, F. Meric-Bernstam, Presence of both alterations in FGFR/FGF andPI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors. Oncoscience 3, 164–172 (2016)PubMedPubMedCentral

40.

J.W. Lin, X. Li, M.L. Qiu, R.G. Luo, J.B. Lin, B. Liu, PI3K overexpression and PIK3CA mutations are associated with age, tumor staging, and other clinical characteristics in Chinese patients with esophageal squamous cell carcinoma. Genet Test. Mol. Biomarkers 21, 236–241 (2017)CrossRefPubMed

41.

S.B. Edge, C.C. Compton, The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17, 1471–1474 (2010)CrossRefPubMed

42.

L. Barnes, J.W. Eveson, P. Reichart. IARC WHO classification of tumours. Pathology and genetics of head and neck tumours. Third edition. (2005) ISBN-13: 9789283224174

43.

K. Starska, E. Forma, P. Jóźwiak, M. Bryś, I. Lewy-Trenda, E. Brzezińska-Błaszczyk, A. Krześlak, Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumour Biol. 36, 2309–2321 (2015)CrossRefPubMed

44.

K. Starska, E. Forma, M. Nowacka-Zawisza, I. Lewy-Trenda, P. Ciesielski, W. Pietruszewska, M. Skóra, M. Bryś, The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma. Tumour Biol. 37, 4541–4557 (2016)CrossRefPubMed

45.

K. Starska, E. Forma, P. Jóźwiak, I. Lewy-Trenda, M. Danilewicz, O. Stasikowska-Kanicka, M. Skóra, K. Kolary, J. Miazga, A. Krześlak, M. Bryś, Gene/protein expression of CAPN1/2-CAST system members is associated with ERK1/2 kinases activity as well as progression and clinical outcome in human laryngeal cancer. Tumour Biol. 37, 13185–13203 (2016)CrossRefPubMed

46.

E. Forma, K. Wójcik-Krowiranda, P. Jóźwiak, A. Szymczyk, A. Bieńkiewicz, M. Bryś, A. Krześlak, Topoisomerase IIβ binding protein 1 c.*229C>T (rs115160714) gene polymorphism and endometrial cancer risk. Pathol. Oncol. Res. 20, 597–602 (2014)CrossRefPubMed

47.

S. Zheng, C. Yang, M. Lu, Q. Liu, T. Liu, F. Dai, X. Gao, I. Sheyhidin, X. Lu, PIK3CA promotes proliferation and motility but is unassociated with lymph node metastasis or prognosis in esophageal squamous cell carcinoma. Hum. Pathol. 53, 121–129 (2016)CrossRefPubMed

48.

T. Helsten, S. Elkin, E. Arthur, B.N. Tomson, J. Carter, R. Kurzrock, The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer. Res. 22, 259–267 (2016)CrossRefPubMed

49.

J. Taeger, C. Moser, C. Hellerbrand, M.E. Mycielska, G. Glockzin, H.J. Schlitt, E.K. Geissler, O. Stoeltzing, S.A. Lang, Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol. Cancer Ther. 10, 2157–2167 (2011)CrossRefPubMed

50.

R. Paduch, The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol 39, 397–410 (2016). https://doi.org/10.1007/s13402-016-0281-9

Title: Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer
Authors: Katarzyna Starska
Ewa Forma
Iwona Lewy-Trenda
Olga Stasikowska-Kanicka
Michał Skóra
Magdalena Bryś
Publication date: 01-06-2018
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 3/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-017-0367-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications

Diagnostic and prognostic relevance of salivary microRNA-21, -125a, -31 and -200a levels in patients with oral lichen planus - a short report

Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1

Concomitant high expression of ERα36, GRP78 and GRP94 is associated with aggressive papillary thyroid cancer behavior

Inhibition of autophagy enhances DENSpm-induced apoptosis in human colon cancer cells in a p53 independent manner

Genetics of personalized medicine: cancer and rare diseases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer